Activity Overview
The ACR Convergence Replay includes six popular video lectures from scientific sessions at ACR Convergence 2024, plus a Q&A session for each.The lectures encompass a variety of topics, including systemic sclerosis, rheumatoid arthritis-related interstitial lung disease, juvenile dermatomyositis, and the use of AI documentation in rheumatology.
The activity includes the following sessions:
Optimizing the Management of Skin Disease in Systemic Sclerosis: Using Clinical Features and Novel Disease Activity Measures to Guide Treatment Decisions
Are We Putting the CAR-T Before the Horse?
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping
AI: The Next Breakthrough in Documentation for Rheumatology
Anti-MDA5 Juvenile Dermatomyositis: ClinicalPresentation and Treatment
Year in Review
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
ACR/ARP Member: $299
ACR/ARP Potential Member: $399
Target Audience
Rheumatologists, internists, primary care providers, physician assistants, residents, fellows in training, advanced practice nurses, students, rheumatology interprofessionals who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.
Learning Objectives
Upon completion of this activity, participants should be able to:
Analyze and explain recent scientific and clinical advancements in understanding the pathogenesis of rheumatic diseases
Evaluate and demonstrate proficiency in diagnosing and managing a range of rheumatic diseases and conditions
Apply evidence-based strategies to effectively manage emerging challenges in rheumatic conditions
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by April 3, 2028, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 8.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias.To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in this activity and were able to change or influence the content of the activity have disclosed to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence Replay 2024 Financial Relationship Disclosures
Acknowledgment of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
This lecture is about the new Lupus Nephritis (LN) guidelines. This session describes the new lupus nephritis guideline, which was based on a standardized protocol that prioritized relevant clinical questions about LN treatments and a systematic literature review.
Target Audience
Rheumatologists, physicians, and primary care providers who care forpatients with rheumatic diseases, and those interested in or engaged in rheumatology research.
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss with a colleague how the new lupus nephritis guidelines were developed
Explain to a colleague or patient the newest diagnostic recommendations for lupus nephritis
Explain to a colleague or patient the newest recommendations for the management of lupus nephritis
CE & MOC Information
This activity is not eligible for CME/MOC.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
This session in the ACR Convergence 2024 Replay series is a recorded webinar thattook place on April 15, 2025. The series features popular scientific sessions followed by a Q&A with the faculty.
This session is about the latest advancements and challenges in the management of ANCA-associated vasculitis (AAV). Although treatment guidelines have become available, many questions persist about their specific application to different clinical scenarios and the patient population with ANCA-associated vasculitis (AAV).
Target Audience
Rheumatologists, primary care providers, practice administrators, and healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.
Learning Objectives
Upon completion of this activity, participants should be able to:
Review general and specific applications of the American College of Rheumatology/Vasculitis Foundation treatment guidelines for GPA andMPA
Discuss recent data regarding use of low versus standard dose glucocorticoids in AAV
Discuss and review applications for avacopan in AAV
Discuss and review current indications forplasmapheresis in AAV
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by May 7, 2028, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 1.25AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence 2024 Replay Controversies in the Treatment of ANCA-Associated Vasculitis Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Information
This session in the ACR Convergence 2024 Replay series is a recorded webinar that took place on June 12, 2025. The series features popular scientific sessions followed by a Q&A with the faculty.
This session features dermatologists with expertise in diseases in skin of color and systemic sclerosis and its mimics. It includes updates in the management of psoriasis from a dermatologist’s perspective, which may differ from the way we approach patients with musculoskeletal involvement.
Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.
Target Audience
Rheumatologists, dermatologists, and rheumatology interprofessionals who care for patients with rheumatic diseases.
Learning Objectives
Upon completion of this activity, participants should be able to:
Recognize how rheumatic disease appears in skin of color and recognize the challenges that lead to disparities in this patient population as they pertain to skin disease
Differentiate the skin manifestations of systemic sclerosis and its mimics and describe therapies for each
Delineate the dermatologist’s perspective for psoriasis management
CE & MOC Information
Credit must be claimed by July 9, 2028, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
Accreditation Statement
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence Replay: More Than Skin Deep: What Rheumatologists Should Know About the Skin Financial Relationship Disclosures
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
Activity Overview
The Rheumatology Review Course features key updates covering a wide range of rheumatology diseases. The activity contains eight lectures recorded at ACR Convergence 2024. Each session is approximately 45 minutes and includes a Q&A session.
The Review Course lectures include:
To Be or Not to Behcet’s? Differentials for Oral Ulcers
Psoriatic Arthritis Management Review
Geriatric Concerns in Rheumatology
Updates in Sarcoidosis
Pain Management for the Rheumatologist
Beyond the Surface: Management of Calcinosis in Connective TissueDiseases
Case-Based Approach to Metabolic Bone Disease
Challenging Cases in Rheumatoid Arthritis
Registration is discounted for ACR/ARP members. If you are not a member, consider joining the ACR/ARP.
ACR/ARP Member: $399
ACR/ARP Potential Member: $599
Target Audience
Rheumatologists, physicians, primary careproviders, fellows in training, physician assistants, advanced practice nurses,nurses, occupational therapists, physical therapists, pharmacists, residents,rheumatology interprofessionals, professionals interested in or engaged inrheumatology research.
Learning Objectives
Upon completion of this activity, participantsshould be able to:
Apply the concept of complex aphthosis
Identify active disease in each PsA domain
Describe the unique aspects and considerations when caring for older adults with rheumatic diseases
Recognize areas of practice vulnerability to disparity, racism, and bias
Identify what calcinosis is in connective tissue diseases
Identify presentation, work-up, and treatment for hypophosphatasia
Discuss recent data informing therapeutic options available in an MTX-IR patient
Implement strategiesto address multi-morbidity in management of RA and D2T RA
CE & MOC Information
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
Credit must be claimed by December 18, 2027, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for diplomates to the diplomate number and date of birth provided when you claimed credit. Points are sent nightly to ACCME and then transferred to physician portals. Please allow at least 48 hours for points to display in the portal.
AMA Designation Statement
The American College of Rheumatology designates this Enduring Material for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Financial Relationship Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Planning/Faculty Team Members
The following planning/ faculty team members have the following financial relationships with ineligible companies to disclose.
Johannes Nowatzky, MD - Soligenix: Advisor or Review Panel Member (Ongoing)
Ana-Maria Orbai, MD, MHS - AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Janssen: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
Namrata Singh, MD,MSc – Mustang Bio; Consultant
Julie Paik, MD, MHS - Alexion: Grant/Research Support (Ongoing); ArgenX: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Guidepoint: Consultant (Ongoing); Priovant: Grant/Research Support (Ongoing)
Lesley Ann Saketkoo, MD, MPH - Kyverna: Grant/Research Support (Ongoing); Mallinckrodt: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing)
Daniel Clauw, MD - Tonix: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Pfizer, Lilly; Lundbeck; Virios; Swing; Neurometrix; Consultant (Ongoing)
Antonia Valenzuela, MD, MS – Board Member: SCTC (Secretary), Grant/Research Support: SCTC/PANLAR
Laura Carbone, MD, MS – Grant funded research; NIH/NIA, R01AG079118, Calculator for Length of Use of Bisphosphonates (CLUB); Department of Defense (DOD), SCI200001, Development of Novel Soluble Epoxide Hydrolase Inhibitotor as a Strategy for Treating Neuropathic Pain in Patients with Spinal Cord Injury; Off-label medication with supporting evidence will be discussed.
Iain McInnes, PhD, FRCP - AbbVie: Consultant(Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing);Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing);Cabaletta: Consultant (Ongoing), Stock options or bond holdings in a for-profitcorporation or self-directed pension plan (Ongoing); Causeway Therapeutics:Consultant (Ongoing), Stock options or bond holdings in a for-profitcorporation or self-directed pension plan (Ongoing); Compugen: Consultant(Ongoing), Stock options or bond holdings in a for-profit corporation orself-directed pension plan (Ongoing); Dextera: Stock options or bond holdingsin a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly:Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant(Ongoing), Grant/Research Support (Ongoing); Moonlake: Consultant (Ongoing);NHS GGC: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing),Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Sanofi:Consultant (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support(Ongoing); Versus Arthritis: Trustee Status (Ongoing)
Review Team Members
The following review team members have no relevant financial relationship(s) with ineligible companies to disclose.
Adena Batterman, LCSW, MSW
Rebecca Manno, MD, MPH
Carlos Ferreira, MA
Planning Team Members
The following planning team members have no relevant financial relationship(s) with ineligible companies to disclose.
Kai Sun, MD, MS, RhMSUS
Myria Stanley, MS, DES
Sharon Ross
Priyanjali Pulipati, MBBS
Noelle Rolle, MBBS, FACP, FACR
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.
